A Study to Evaluate the Pharmacokinetics of Apatinib in Subjects With Impaired Renal Function : A Multi-center, Non-randomized, Open-label, Parallel Study to Evaluate the Pharmacokinetics of Apatinib Mesylate in Subjects With Impaired Renal Function and Healthy Subjects
The primary objective of the study is to compare the pharmacokinetics of apatinib in subjects with impaired renal function and healthy subjects, to give dose recommendations for patients with impaired renal function..
| Medienart: |
|
|---|
Klinische Studie| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
ClinicalTrials.gov - (2020) vom: 04. Juni Zur Gesamtaufnahme - year:2020 |
|---|
| Sprache: |
Englisch |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
610 |
|---|
| Anmerkungen: |
Source: Link to the current ClinicalTrials.gov record., First posted: June 4, 2020, Last downloaded: ClinicalTrials.gov processed this data on June 14, 2021, Last updated: June 15, 2021 |
|---|
| Study ID: |
NCT04414852 |
|---|---|
| Veröffentlichungen zur Studie: |
|
| fisyears: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
CTG003412148 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | CTG003412148 | ||
| 003 | DE-627 | ||
| 005 | 20230425221535.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 210408s2020 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)CTG003412148 | ||
| 035 | |a (UBBS_Klinische_Studien)NCT04414852 | ||
| 035 | |a (UBBS_Klinische_Studien)HR-APTN-I-011 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 245 | 1 | 0 | |a A Study to Evaluate the Pharmacokinetics of Apatinib in Subjects With Impaired Renal Function |b A Multi-center, Non-randomized, Open-label, Parallel Study to Evaluate the Pharmacokinetics of Apatinib Mesylate in Subjects With Impaired Renal Function and Healthy Subjects |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Source: Link to the current ClinicalTrials.gov record., First posted: June 4, 2020, Last downloaded: ClinicalTrials.gov processed this data on June 14, 2021, Last updated: June 15, 2021 | ||
| 520 | |a The primary objective of the study is to compare the pharmacokinetics of apatinib in subjects with impaired renal function and healthy subjects, to give dose recommendations for patients with impaired renal function. | ||
| 650 | 2 | |a Renal Insufficiency | |
| 650 | 4 | |a Medical Condition: Subjects With Impaired Renal Function and Healthy Subjects | |
| 650 | 4 | |a Study Type: Interventional | |
| 650 | 4 | |a Recruitment Status: Not yet recruiting | |
| 650 | 4 | |a Phase: Phase 1 | |
| 650 | 4 | |a 610 | |
| 773 | 0 | 8 | |i Enthalten in |t ClinicalTrials.gov |g (2020) vom: 04. Juni |
| 773 | 1 | 8 | |g year:2020 |g day:04 |g month:06 |
| 856 | 4 | 0 | |u https://clinicaltrials.gov/show/NCT04414852 |z kostenfrei |3 Volltext |
| 912 | |a GBV_CTG | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |j 2020 |b 04 |c 06 | ||